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Abstract
Background: Generation Scotland: the Scottish Family Health Study aims to identify genetic
variants accounting for variation in levels of quantitative traits underlying the major common
complex diseases (such as cardiovascular disease, cognitive decline, mental illness) in Scotland.
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BMC Medical Genetics 2006, 7:74 http://www.biomedcentral.com/1471-2350/7/74Methods/Design: Generation Scotland will recruit a family-based cohort of up to 50,000
individuals (comprising siblings and parent-offspring groups) across Scotland. It will be a six-year
programme, beginning in Glasgow and Tayside in the first two years (Phase 1) before extending to
other parts of Scotland in the remaining four years (Phase 2). In Phase 1, individuals aged between
35 and 55 years, living in the East and West of Scotland will be invited to participate, along with at
least one (and preferably more) siblings and any other first degree relatives aged 18 or over. The
total initial sample size will be 15,000 and it is planned that this will increase to 50,000 in Phase 2.
All participants will be asked to contribute blood samples from which DNA will be extracted and
stored for future investigation. The information from the DNA, along with answers to a life-style
and medical history questionnaire, clinical and biochemical measurements taken at the time of
donation, and subsequent health developments over the life course (traced through electronic
health records) will be stored and used for research purposes. In addition, a detailed public
consultation process will begin that will allow respondents' views to shape and develop the study.
This is an important aspect to the research, and forms the continuation of a long-term parallel
engagement process.
Discussion: As well as gene identification, the family-based study design will allow measurement
of the heritability and familial aggregation of relevant quantitative traits, and the study of how
genetic effects may vary by parent-of-origin. Long-term potential outcomes of this research include
the targeting of disease prevention and treatment, and the development of screening tools based
on the new genetic information. This study approach is complementary to other population-based
genetic epidemiology studies, such as UK Biobank, which are established primarily to characterise
genes and genetic risk in the population.
Background
Most medical disorders of public health importance have
a significant heritable component. This includes cancer,
heart disease/stroke and mental health (the three current
health priorities in Scotland) [1], as well as a wide range
of chronic or currently untreatable causes of ill health.
With the current changes in the demographic profile of
Western society, including Scotland [2], there will be a
steady increase in the prevalence of chronic disease over
the next two decades. With few exceptions, however the
specific nature of the heritable risk factors for chronic dis-
ease remains elusive. As a result of the successful comple-
tion of the human genome project [3-5], there is an
opportunity to identify and characterise these heritable
(genetic) risk factors. In the long term this will inform and
potentially improve disease surveillance, treatment opti-
misation, avoidance of adverse drug events and prediction
of response to therapy (pharmacogenetics), health care
planning and drug discovery (pharmacogenomics) [6-8].
The benefits of such research to individuals and society
are potentially substantial.
Funding and collaborations
Generation Scotland (GS) is a collaborative initiative
between the Universities of Aberdeen, Dundee, Edin-
burgh, Glasgow and St Andrews, and the Medical
Research Council Human Genetics Unit, the National
eScience Centre, the Scottish School of Primary Care, and
the National Health Service (NHS) Scotland. It is funded
by the Scottish Funding Council (formerly Scottish
Higher Education Funding Council), and aims to pro-
mote research into genetics and healthcare [9]. Genera-
tion Scotland: the Scottish Family Health Study
(GS:SFHS) is the first major study undertaken by GS, and
has been funded by the Scottish Executive Health Depart-
ment, Chief Scientist Office (SEHD CSO) under their
Genetics and Healthcare Initiative [10], to bring together
existing and complementary strengths in Scotland in the
arena of genetics as applied to healthcare.
Aims and objectives
The aim of GS:SFHS is to establish a new, large, family-
based intensively-phenotyped cohort recruited from the
general population across Scotland, as a resource for stud-
ying the genetics of health areas of current and projected
public health importance. DNA and non-identifiable
information from this cohort will be made available to
researchers in Scotland and international collaborators. It
will be a six-year fieldwork programme, beginning in
Glasgow and Tayside in the first two years (Phase 1)
before extending to other parts of Scotland in the remain-
ing four years (Phase 2).
The objectives are:
1. Recruitment. To recruit and phenotype a family-based
cohort from across Scotland, allowing identification of
genetic variants relevant to the pathogenesis of common
complex diseases (including cardiovascular disease, age-Page 2 of 9
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cogenetics research.
2. Public Understanding. To conduct an early and sus-
tained public consultation programme to understand and
explain the public reaction to genetics in healthcare, and
their reaction to participation in research.
3. Research capacity. To create a multi-institutional and
NHS collaboration across Scotland that will share knowl-
edge and best practice in human genetics research.
4. Health informatics. Through this collaboration, to cre-
ate a nationwide research platform in emerging technolo-
gies of health informatics in genetics research, including
the linkage of study data to "real-time" routine healthcare
data on an individual basis.
5. NHS integration. To work with NHS Clinical Genetics
colleagues to develop computer-delivered education on
genetics for healthcare professionals in Scotland.
6. Exemplar studies. To conduct specific research projects
with identified protocols in the areas of cardiovascular
disease, mental health, osteoporosis and pharmacogenet-
ics, using the resource that will be established.
This paper describes the methodology for the first of these
objectives, currently in its pilot phase, though it is impor-
tant that all of the objectives are closely integrated. In par-
ticular, findings from the public consultation will
contribute directly to continuous development of the
materials and methods used to recruit the cohort, and the
study will undergo periodic review in light of the findings
of this parallel component. This will include study of
potential participants' views on recruitment, consent,
withdrawal, feedback, confidentiality, storage of and
access to bioinformation, commercialisation, governance
and other associated ethical, legal and social issues. This
article therefore discusses the structure and form of a nas-
cent GS.
Methods and design
Identification and recruitment of participants
This is a family-based study, recruiting participants and
their relatives mainly through primary care. Recruitment
of general practices is facilitated by Scottish Practices and
Professionals Involved in Research (SPPIRe) [11]. Poten-
tial participants are identified from the registers of collab-
orating general practices via the Community Health
Number, a unique identifying number allocated to every
individual in Scotland who is registered with a general
practitioner (GP), ie approximately 96% of the popula-
tion. They are eligible to participate if they are aged
between 35 and 55 years and have at least one first degree
relative aged 18 years or over, and at least one full sibling
group (the larger the better) in the participating family
group.
An independent party, based in the NHS, generates a list
of eligible people registered with each collaborating gen-
eral practice, from the Scottish NHS register (known as the
Community Health Index (CHI)). The names of all poten-
tial participants are screened by their GP, and individuals
whom it might be inappropriate to approach (such as
those with a serious or terminal illness, or those unable to
consent) are excluded. Letters of invitation to eligible par-
ticipants are generated on practice headed note-paper and
signed by one of its GP Principals. These letters are dis-
patched by the independent party by post, with up to two
reminders as required. This invitation is for agreement to
discuss the study with family members with a view to pos-
sible participation. When the eligible person returns the
tear-off slip agreeing to be contacted by the research team
the individual's details are sent from the independent
party to the study team.
In addition, targeted approaches in the Tayside area will
be made to potentially eligible individuals whose details
are held on the Walker Birth Cohort database [12]. This is
a database of over 48,000 births in Dundee between 1952
and 1966, identified by CHI numbers, and therefore with
current information about family structure and location.
This provides the opportunity to approach individuals
and their families simultaneously, with the ability to max-
imise the efficiency of recruitment by targeting larger local
families in the first instance.
Upon receiving their permission, potential participants
are contacted by a member of the research team to ensure
that participants understand the study, that all demo-
graphics and details are accurate, and to discuss participa-
tion in the study with the relevant first degree relatives
(including at least one sibling group). The names and
contact details are requested of all first degree relatives
who have verbally indicated, to the individual initially
contacted, their willingness to be approached by the
research team. These relatives are then also contacted by
telephone by the study team. Each relative contacted is
invited to discuss with and identify further first degree rel-
atives, and so on, with the aim of creating a "snowball"
sampling effect.
Similar methods of approaching and recruiting partici-
pants and their relatives have been successfully used in
other studies in which several of the co-applicants have
been closely involved. These include the British Genetics
of Hypertension (BRIGHT) study [13] and "Family and
population genetic studies in major mental illness" (D
Blackwood et al). Although it is the main method ofPage 3 of 9
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gramme of communication and publicity about the study.
Throughout this programme, individual families will be
invited to volunteer directly for the study, by contacting
the research team. They will be able to participate if the
family includes at least one sibling pair.
Data to be collected
Following verbal consent, individuals and their relatives
who agree to consider participation in the clinical study
are sent a copy of the Participant Information Leaflet
(PIL), a consent form, and a pre-clinic questionnaire
(PCQ), and arrange for attendance at a research clinic at a
mutually convenient time and location. They are asked to
bring these and any medications taken regularly, to the
clinic visit. If possible, this appointment is at a time that
allows collection of a fasting blood sample. The feasibility
of this is being reviewed as the study progresses.
On attendance at the clinic the consent form is discussed
and completed prior to any sample or medical details
being taken. The participant then hands over the com-
pleted PCQ, with the opportunity for clarification of any
items with the research nurse, has clinical and interview
measurements made, and provides blood and urine sam-
ples, all according to detailed Standard Operating Proce-
dures (SOPs). This visit lasts between 90 minutes and two
hours.
The data collected aim to maximise the research benefit of
each individual's attendance while retaining efficiency
and acceptability. As well as the PCQ, they include bio-
metric measurements, tests of cognitive function, ques-
tionnaires relating to personality traits and psychological
distress, and screening for major mental illness (Table 1).
Validated questionnaire instruments and clinical SOPs are
used where these are available. The clinic processes are
subject to regular internal monitoring for adherence to
SOPs and protocol.
Demographic, clinical and biological data are entered ini-
tially on a paper clinical reporting form (CRF), but kept
separately from any personal details that would allow
identification of individuals, using a barcode system. The
PCQ and CRF are scanned into an electronic database,
with detailed in-built validity checks of data recording.
Feedback is given to participants and, with their permis-
sion, their GP, in the form of basic clinical information
(height, weight, body mass index, blood pressure, serum
cholesterol and glucose, and smoking status). ECGs are
reported centrally, and summarised results are also fed
back to GPs, with permission. Detailed results of these are
returned to the research team for entry to the database,
and summarised results are fed back to GPs (with the par-
ticipants' consent), along with basic clinical recommen-
dations based on these.
Planned analysis, statistical power
The primary objective of this study is to establish the
cohort and database as a resource for future analysis. It is
important to maximise the utility of the resource, and
some general principles of analysis have been determined.
We propose to adopt both variance components linkage
and regression approaches to the genetic linkage analysis
of continuous quantitative trait data (QT) since these have
been shown to be powerful approaches [14]. This will be
complemented by using parent-offspring groups to carry
out family-based association analysis in the regions of the
QT loci (QTLs) identified in the linkage study. The power
of variance components linkage analysis varies, according
to the specific genetic and environmental effects and com-
ponents of variance used to model the phenotypic mean,
and the resemblance between pedigree members. A pre-
cise estimate for the statistical power of the study requires
Table 1: Data collected from participants in GS:SFHS
1. Pre-clinic questionnaire
a. Demographic details
b. Occupational history
c. Lifestyle – smoking, alcohol, diet, exercise and participation in 
sports
d. Personal and family medical history
e. Rose angina questionnaire
f. Musculoskeletal questions – including chronic pain, fractures, joint 
replacements, HRT use, age at
menarche and menopause
g. Current drug history, including prescribed and some non-
prescribed,
2. Physical measurements
a. Height, weight
b. Blood Pressure × 2, resting pulse
c. Ankle brachial pressure index
d. Spirometry
e. Electrocardiograph
f. Bioimpedance
3. Personality, Cognitive function, and Psychological distress 
measurements
a. Eysenck Personality Questionnaire Revised Short Form[27]
b. Logical Memory from the Wechsler Memory Scale III[28]
c. Digit Symbol from the Wechsler Adult Intelligence Scale III[29]
d. Verbal Fluency[30]
e. Mill Hill Vocabulary Scale[31]
f. General Health Questionnaire-28[32]
4. Mental health measurements
a. SCID Brief screening interview for major depression[33]
5. Biological samples
a. Blood: EDTA for DNA – 2 × 4.7 ml, 1 × 9 ml;
Clot activator with gel separator for serum – 3 × 5 ml
Fluoride oxalate for glucose – 1 × 2 ml
b. Urine: Stored for future proteomics analysisPage 4 of 9
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is not yet known. Nevertheless, a general statement
regarding the power of the study can be made. Calcula-
tions and simulations performed by Williams and Blang-
ero [14] have shown that each of the following family
structures would have 80% asymptotic power to detect a
QTL of heritability 0.10 (0.15) [0.2] with a LOD score of
greater than 3, indicating evidence of linkage:
15,000 (7,500) [4,000] sibpairs, thus requiring recruit-
ment of 30,000 (15,000) [8,000] individuals
4,700 (2,400) [1,333] sibtrios thus requiring recruitment
of 14,400 (7,200) [4,000] individuals
2,400 (1,200) [625] sibquads thus requiring recruitment
of 9,600 (4,800) [2,500] individuals
78 (38) [21] pedigrees each of 48 members thus requiring
recruitment of 3,750 (1,800) [1,000] individuals
Our recruitment is based on families with a minimum of
a sibpair. However, we seek to recruit all siblings within
families that are recruited, and aim to recruit as many sib-
trios as possible. Recruitment of parents and adult off-
spring will further increase study power and will permit
future family-based association studies and haplotype
analysis. We therefore also seek to recruit one or both par-
ents, wherever possible. If we take the power estimates for
sibtrios as our main estimate then in ideal circumstances
we will require to recruit 14,400 (7,200) sibs to be able to
identify a QTL with an effect corresponding to QTL herit-
ability of 10% (15%). The proposed cohort size over the
first 2 years will effectively be between these two esti-
mates. Actual study power will be increased by the inclu-
sion of parental data and will increase in proportion to
our success in recruiting some larger pedigrees but will be
decreased by any genotyping errors (errors in family rela-
tionship data should be identified as part of the genetic
analysis), QT measurement error and imperfect reliability
(repeatability) of QT measures. We believe that a study
power calculation based on that for sibtrios is a reasona-
ble compromise and suggest that the study will have 80%
power to detect a QTL heritability of between 10% and
15%. We will further maximise study power by selecting
traits for study based on their known (high) heritability
and repeatability. If we are successful in targeting and
recruiting larger families then the above power calculation
will be very conservative and significantly underestimate
the true study power. As recruitment rises towards 50,000
in years three to six this will give study power to detect
QTL heritability of between 5% and 10%.
Data and sample storage
Questionnaire and interview data are optically scanned in
to a secure database with a unique study number identify-
ing each individual. Biochemical samples are processed
by local NHS laboratories, and the data entered on to the
same secure database. Further biochemical samples
(serum and urine) are processed locally in research labs
and archived for future analysis. A 9 ml EDTA blood sam-
ple will be delivered (in batches of frozen tubes) to the
Wellcome Trust Clinical Research Facility in Edinburgh
[15], for DNA extraction to master and working stocks
and further dissemination to researchers around Scotland
and internationally, for specific hypothesis-driven analy-
ses and with proper ethical and other relevant approvals.
Precise access agreement is being defined according to
Table 2: Healthcare datasets with which GS:SFHS data will be linked.
DATASET DESCRIPTION COVERAGE DATES
CHI dataset NHS number (unique personal identifier) (Includes DOB/death) Scotland wide, currently 5.6M people 1980-present
ISD SMR1 record All hospital admissions – ICD9/10 coded Scotland wide, currently 750k p.a. 1980-present
MEMO- Rx Regional prescribing of all pharmacies Tayside wide 1993-present
Mobile Eye Screening Mobile digital retinal photographic unit All GPs; total 33,000. 1991-present
Tayside Biochemistry All biochemical investigations Tayside wide, 25M data items 1993-present
Retinal Laser Clinic Regional laser clinic Tayside 1998-present
DARTS Validation All diabetes patients Tayside wide-all 78 GP Practices 1994-present
Cardiac outcomes Coronary Care Unit admissions, echocardiography, Exercise 
Tolerant Tests, etc.
Tayside 1997-present
Walker Database Tayside birth records from 1952–66 Tayside, 50k births; 73 data items 1952–1966
ISD SMR 2, 6, 10,11 Maternity, cancer, neonatal, child health records Tayside 1980-present
GPASS data Primary care clinical and prescribing data Being rolled out to 65 GP practices ongoing
HEARTS All cardiac admissions Tayside wide 1996-present
Endoscopy All clinic data Tayside 1990-present
Stroke All Tayside strokes Tayside 1993-present
Asthma A cohort of 4,500 asthma patients Tayside 1990-present
Note. Although some of these are currently only available in the Tayside region, it is intended that the capacity will be exported across the rest of 
Scotland as part of this study.Page 5 of 9
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[16].
IT infra-structure and data linkage
An important part of GS:SFHS is the development of an IT
infra-structure that can support the research, from identi-
fication of potential participants to linkage of data with
other useful databases. This both facilitates the study and
maximises its value. A suite of Windows-based applica-
tions and services, implemented with web services, pro-
vides access to IT facilities for identification, approach and
recruitment of subjects, appointments, consent, storage of
paper-based data, and feedback of clinical information.
Participants are identified by a unique barcode, with sys-
tems to ensure efficient and confidential handling of all
data.
Through the CHI numbers of participants, and by a proc-
ess of encryption, study data will be linked to a number of
routine datasets, including virtually all formal healthcare
activity (Table 2). Consent for this is sought at the time of
recruitment. This allows the baseline phenotype data to
be extended from that which will be collected specifically
for the study, and will also allow longitudinal collection
of real-time health data for the foreseeable future. This
linkage and data collection is already possible in the Tay-
side area, and extension of this facility to the rest of Scot-
land will be part of the developmental process of this
study. One key methodological resource relevant to the
study is the ability to link to all prescribed drugs dis-
pensed to patients in Tayside, and increasingly through-
out Scotland. The confirmed ability [17,18] to link large
and comprehensive clinical datasets to extensive drug pre-
scription records at an individual level, over a ten year
period, is not available anywhere else in the world.
Ethical issues
All components of GS:SFHS, including the protocol and
written study materials, have received formal, national
ethical approval from NHS Tayside Research Ethics Com-
mittee (REC reference number 05/S1401/89). In addition
local approval has been obtained from NHS Glasgow
Research Ethics Committee, and from NHS Glasgow and
NHS Tayside Research and Development Offices, as is
required.
The study aims to minimise several risks to participants.
Initial contact and recruitment
1. Direct researcher contact maximises subject accrual but
at the risk of compromising privacy and confidentiality.
The use of an independent party to work between the
research team and participating general practices is
designed to minimise the risk to the privacy of potential
participants. We need to ascertain what the actual recruit-
ment rate will be, and the incorporation of the public con-
sultation study will ascertain what issues are likely to
affect participation, and how these might be addressed.
2. Heightened risk of disclosing confidential information.
No information is given by the research team to probands
or relatives about each other, and only basic lifestyle and
health information will be fed back to participants. Sepa-
rate discussions between the research nurse and both the
proband and the relative(s) maintain confidentiality, and
allow individual concerns to be addressed and a private
and frank discussion about participation to ensue.
3. Because it is impossible to know what precise purposes
the resources will be used for in the future, fully informed
consent for the use of data and DNA cannot be obtained.
Because of the need to maintain participant anonymity
and confidentiality, the logistical difficulties of re-tracing
participants and the annoyance factor of persistent re-con-
senting, currently "blanket" consent is sought, for full
research and commercialisation purposes.
Participation
1. Despite this being a family study, individual confiden-
tiality remains paramount and no medical information is
given to individuals or relatives about themselves or each
other, apart from personal lifestyle and basic clinical
information to individuals who request this at the time of
collection.
2. We emphasise that participation is at all times volun-
tary. Withdrawal will be allowed at any time, upon which
all data and samples, that have not been analysed, relating
to the withdrawing participant will be destroyed.
3. Bias will be introduced into both the clinical and con-
sultation study in recruitment of family members by the
proband. Family is not purely about biological connec-
tions but social and kinship networks. The design offers
no option other than to go with the family's choice in who
can participate, and their stated biological relationships
with each other.
4. No genetic feedback will be given to participants; this is
a project that aims to construct a database for research
purposes and does not purport to offer genetic tests either
to individuals or populations.
5. Access to the samples and data by third parties will be
reviewed by GS:SFHS senior management groups, subject
to an independent governance system whose details are to
be finalised in light of the public consultation study and
external stakeholder advice, and NHS Research Ethics
Committees. Data will only be made available to outsidePage 6 of 9
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removed and/or securely encrypted.
The REC will be informed of progress and proposed mod-
ifications to the protocol. In addition, an independent GS
Advisory Board has been established under the auspices of
SEHD CSO, and will monitor the study's procedures, pro-
tocols and data storage and access. This will be analogous
to a Data Monitoring Committee in a clinical trial, and
will have right of access to all study materials (ano-
nymised when appropriate).
Discussion
Unlike general population biobank studies, such as UK
Biobank [19], GS:SFHS does not focus on gene:environ-
ment interactions, and is not powered for this. Its main
focus – on identifying gene loci associated with important
QTs – means that it will complement UK Biobank and
other studies, and much of the data collection is designed
with this in mind.
Scottish advantages
The Scottish population (currently 5.1 million approxi-
mately [20]) is ideally suited to genetic epidemiological
studies of many important diseases, including cardiovas-
cular, cerebrovascular, metabolic diseases, mental illness
and cancer. The overall incidence, prevalence and mortal-
ity from these diseases is high and premature deaths are
relatively common [21]. In addition, Scotland has a high
prevalence of adverse lifestyle risk factors [22], which
facilitate studies of the interactions between lifestyle and
genetic factors. A further advantage of Scotland is its rela-
tively stable population. A complete follow-up is most
likely to be achieved if the study recruits people who con-
tinue to reside in the same geographical area and remain
registered with the same general practitioner. The annual
migration rate from Scotland is less than 1%, and there is
clear evidence that emigration from Scotland to other
areas of the United Kingdom is lower than any other
region [23]. In addition past experience has shown that
the Scottish people are supportive of community based
cohort studies [13].
Unique features of GS:SFHS
GS:SFHS is one of a growing number of large DNA collec-
tions or biobanks across the world. Two important unique
characteristics of GS:SFHS will be (i) the large general
population family-based nature, and (ii) the ability to
link individual data with detailed past and future health
records. It is also unique for its inclusion of detailed cog-
nitive function phenotype information, and its collection
of data on serious mental illness, both of which will pro-
vide rich opportunities to study the genetics of these
health areas.
Data linkage
The key parts of GS:SFHS are the desire to intensively phe-
notype family members at baseline and to follow up par-
ticipants through routine data systems and to seek their
consent for further fieldwork. Scotland is uniquely well-
placed to allow linkage of participants' collected data with
routine data from the NHS because of the widespread use
of unique CHI numbers linking individuals, through the
CHI, with many other NHS datasets. A bioinformatic
infrastructure is well-developed to support research that
maximizes the value of this while retaining the anonymity
of participants. Tayside is currently the only region in the
UK where the CHI number is used as the patient identifier
in the virtually all health care activities, from primary to
tertiary care, from birth to death, and is added routinely to
all research datasets in order to enable further phenotype
enrichment. A core aim of the SFHS is to export expertise
in Tayside to other centres in Scotland.
Advantages of a family based approach
Linkage analysis has proven to be very effective for identi-
fying genes concerned with rare Mendelian disorders and
Mendelian forms of genetically complex ones. Thus, it is
the major strategy used for identification of genetic vari-
ants of large effect.
However large genetic effects tend to result in selection
against these alleles, therefore causing only rare diseases
or rare forms of common diseases. The low power to
detect genetic variants of small effect has suggested that
this approach may be much less effective for common
complex diseases. However, recent pedigree-based studies
carried out by deCODE Genetics in Iceland have reported
promising results with denser marker scans and larger
pedigrees than in past studies [24]. GS:SFHS therefore
aims to recruit large numbers of families using a family-
based approach.
The focus of the study is to identify genetic variants of
moderate rather than large (likely to be already discov-
ered) or small (unlikely to be detectable by this approach)
effect sizes. It is likely that genetic factors with large and
moderately large effects on complex traits or disease risk
code for proteins involved in important physiological
mechanisms. In addition therefore, they are likely to be
important both in terms of our understanding of patho-
logical mechanisms and of their potential to lead to new
prevention or treatment strategies.
This pedigree or family-based approach has a number of
other advantages:
• the ability to make use of familial correlations to
increase power using strategies such as the EDAC
("extreme discordant and concordant") design.Page 7 of 9
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(most readily determined with family data, particularly
over extended genetic distances, despite recent improve-
ments in prediction).
• the ability to carry out a family based association
approach including using the transmission-disequilib-
rium test (TDT) by comparing transmitted with non-
transmitted parental alleles.
• the ability to provide parent-of-origin information (for
example, the relationship between early life events and
adult diseases may involve maternally or paternally
imprinted loci, such as IGF2).
Existing family-based DNA collections
Most family-based collections have been affected sibpair
studies [24], for a number of specific diseases. Most of
these studies have been individually small but have
gained power through international collaborations. There
have been far fewer sibpair studies which have focused on
measurement of a wide range of disease-related QTs, as
this study will, and none of the proposed scale of
GS:SFHS. The other major family-based design has been
twin studies based around a number of national or
regional twin registries in northern European countries,
and these are being developed further through Genome
EU Twins [25]. These have achieved large sample sizes and
several have measured multiple QTs, but the twin design
is substantially less powerful than sibship designs in
which larger family units are recruited. Finally, there are a
few pedigree-based studies which have been conducted in
special genetic isolate populations. These have typically
measured QTs but have been of relatively small size due
to the population constraints in these unique popula-
tions. Thus GS:SFHS complements the recent large popu-
lation-based study and biobank initiatives and the
existing family based collections. Despite its focus on
large sample size it may still be helpful to consider com-
bining pedigree data with other international datasets to
acquire additional power for linkage based approaches.
In summary, the family-based design of this study will
permit both linkage and family-based association study
approaches and the large sample size will give power to
detect moderate genetic effects on QT levels [24,26]. The
QTs studied underlie diseases which account for most of
the burden of disease in Scotland.
Current and future work
GS:SFHS is actively recruiting to the Phase 1 in both Tay-
side and Glasgow. It is intended that data from these par-
ticipants will contribute to the main study database. A
review of the Phase 1 will provide information on, among
other factors, recruitment and participation rates, pedi-
gree size and nature (and therefore power calculations),
and planning for Phase 2 of the study across the whole of
Scotland. These data will be written up for publication as
the study progresses [9].
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